Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Reports Mixed Q2 2025 Earnings, Beats Revenue Estimates and Narrows Loss Ultragenyx Q2 2025 earnings show revenue beat and narrower loss, reaffirming full-year guidance. Shares rose slightly post-report amid mixed market sentiment.
Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks HC Wainwright initiates Ultragenyx at Buy with $80 target, citing strong rare disease pipeline and late-stage data expected by year-end.
FDA Delays Approval For Ultragenyx's Gene Therapy, But Not A Dealbreaker, Says Analyst Ultragenyx's UX111 gene therapy faces FDA delay due to facility issues; analysts adjust price targets amid uncertain resubmission timeline.
Ultragenyx Pharma Takes Another Hit As FDA Slaps Its Gene Therapy With A Rejection The company has a bigger problem than just the FDA rejection, says one analyst. It's timeline to profitability is now longer.
Let's take a look at the stocks that are in motion in today's session. Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
Which stocks are experiencing notable movement on Thursday? Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Thursday's session: gap up and gap down stocks Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session.
Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win Ultragenyx shares fall after Phase 3 study misses interim target, but analysts remain positive ahead of final OI data expected later this year.
Get insights into the top gainers and losers of Thursday's pre-market session. Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
